Month: December 2020

BEIJING, China, Dec. 01, 2020 (GLOBE NEWSWIRE) — Li Auto Inc. (“Li Auto” or the “Company”) (Nasdaq: LI), an innovator in China’s new energy vehicle market, today announced that the Company delivered 4,646 Li ONEs in November 2020, continuing its growth momentum.November was another record-setting month for Li ONE, marked by over 5,000 units produced and an even higher number of new orders.As of November 30, 2020, the Company had 45 retail stores covering 38 cities, and 97 servicing centers and Li Auto-authorized body and paint shops covering 72 cities. To meet the growing demand of its vehicles across China, the Company targets to further expand its direct sales and servicing network while maintaining a high level of sales efficiency.About Li Auto Inc.Li Auto Inc. is an innovator in China’s new energy vehicle market. The Company designs,...

Third quarter total revenue of $777.2 million, up 367% year-over-yearNumber of customers contributing more than $100,000 in TTM revenue up 136% year-over-yearApproximately 433,700 customers with more than 10 employees, up 485% year-over-yearSAN JOSE, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ: ZM) is clarifying the Company’s full fiscal year 2021 non-GAAP diluted earnings per share guidance as disclosed in a press release issued on November 30, 2020. Full fiscal year 2021 non-GAAP diluted earnings per share is expected to be $2.89 to $2.91, instead of $2.85 to $2.87.Zoom Video Communications, Inc. (NASDAQ: ZM), a leading provider of video-first unified communications, today announced financial results for the third fiscal quarter ended October 31, 2020.“We remain focused on the communication...

BANGKOK, Thailand, Dec. 02, 2020 (GLOBE NEWSWIRE) — Juniper Networks (NYSE: JNPR), a leader in secure, AI-driven networks, today announced that ThaiSri, one of Thailand’s largest insurers, has selected Juniper Networks’ AI-driven solutions to upgrade and automate the management of its network infrastructure.With their refreshed AI-driven network, ThaiSri can now centrally manage and orchestrate devices and services, substantially reducing complexity. This has enabled them to quickly deliver new applications and services to the market, while also significantly transforming the digital experience for its large, and exponentially growing, base of customers.With a strong market presence as a leading insurer across Thailand for over 67 years, ThaiSri has been consistently adapting its business to leverage the rapid changes in technology...

OMER, Israel, Dec. 01, 2020 (GLOBE NEWSWIRE) — Medigus Ltd. (Nasdaq, TASE: MDGS), a technology company engaged in advanced medical solutions and innovative internet technologies, today announced the pricing of an underwritten public offering of 7,098,491 American Depositary Shares (the “ADSs”). Each ADS is being sold to the public at a price per ADS of $1.83. The gross proceeds to the Company from this offering are expected to be approximately $13 million before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.The Company has also granted the underwriter a 45-day option to purchase up to an additional 15% of the number of ADSs offered in the public offering...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATESWINNIPEG, Manitoba, Dec. 01, 2020 (GLOBE NEWSWIRE) — Delta 9 Cannabis Inc. (“Delta 9” or the “Company”) (TSX:DN) (OTCQX: VRNDF) is pleased to announce that is has amended the terms of its previously announced offering of Equity Units (as defined below) under the terms of an amended agreement with Leede Jones Gable Inc. as the lead underwriter and sole bookrunner (the “Underwriter”), pursuant to which the Underwriter has agreed to purchase, on a bought-deal basis, 9,090,910 units (the “Equity Units”) for gross proceeds to the Company of $5,000,000.50 (the “Offering”) at a price of $0.55 per Equity Unit.Each Equity Unit will consist of common share of the Company (a “Common Share”) and one half (1/2) of a Common Share purchase warrant (each whole purchase...

バミューダ諸島ハミルトン発, Dec. 02, 2020 (GLOBE NEWSWIRE) — エンスター･グループ･リミテッド (Enstar Group Limited、NASDAQ: ESGR) (以下「エンスター」) は本日、スターストーンU.S. (StarStone U.S. Holdings, Inc.) (以下「スターストーンU.S.」) の売却と資本増強を完了したことを発表した。この取引では、現金とコアスペシャルティ保険 (Core Specialty Insurance Holdings, Inc.) (以下「コアスペシャルティ」) の株式約25%を組み合わせて交換することで、スターストーンU.S.をコアスペシャルティに売却した。規制当局の承認を受け、その他各種の完了条件が満たされたことで、取引は完了した。スカイナイト･キャピタル (SkyKnight Capital, L.P.)、ドラゴニア･インベストメント･グループ (Dragoneer Investment Group)、アクイライン･キャピタル･パートナーズ (Aquiline Capital Partners LLC) とその他 (主に経営陣と取締役) のコアスペシャルティ投資家は、新たな株式資本に対して6億1,000万ドル (約634億4,000万円) を出資した。エンスターの既存の所有権のロールオーバーと経営陣およびその他の投資家からの6,000万ドル (約62億4,000万円) の出資を合わせると、同社の自己資本は9億ドル (約936億円) 以上になる。エンスターがスターストーンU.S.をコアスペシャルティに売却したのに伴い、エンスターの全額出資子会社の1社が、スターストーンU.S.のレガシー準備金に関連して、合成損失ポートフォリオとアドバース･デベロップメント再保険契約を締結した。2020年8月に締結した資本増強契約に従って、エンスターはコアスペシャルティが保有するトライデントV...

LORDSTOWN, Ohio, Dec. 01, 2020 (GLOBE NEWSWIRE) — Lordstown Motors Corp. (Nasdaq: RIDE), (“Lordstown Motors”), a leader in electric light duty trucks focused on the commercial fleet market, today announced that Steve Burns, Chief Executive Officer of Lordstown Motors, will take part in a fireside chat at the Credit Suisse Eighth Annual Virtual Industrials Conference.The discussion will be webcasted live and will take place on Wednesday, December 2, 2020 from 2:30 p.m. EST to 3:00 p.m. EST. In order to sign up for and access the event, please click here.About Lordstown Motors Corp.Lordstown Motors Corp. is an Ohio-based original equipment manufacturer of light duty fleet vehicles, founded by CEO Steve Burns with the purpose of transforming Ohio’s Mahoning Valley and Lordstown, Ohio, into the epicenter of electric-vehicle manufacturing....

GUANGZHOU, China, Dec. 01, 2020 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to a public secondary offering by certain selling shareholders (the “Offering”) of 1,838,000 American Depositary Shares (“ADSs”), each representing one Class A ordinary share of the Company. The selling shareholders have granted the underwriters an option, exercisable within 30 days from the date of the final prospectus, to purchase up to 275,700 additional ADSs.The Company will not receive any proceeds from the sale of the ADSs by the selling shareholders.Morgan...

TORONTO, Dec. 01, 2020 (GLOBE NEWSWIRE) — Petrolympic Ltd. (the “Company“) (TSX-V:PCQ – OTCQB:PCQRF) is pleased to announce the closing of a non-brokered private placement (the “Offering“), consisting of 1,666,667 units (“Units“) at a price of $0.06 per Unit to raise aggregate gross proceeds of $100,000.Each Unit consists of one common share (“Common Share“) of the Company and one Common Share purchase warrant (“Warrant“). Each Warrant entitles the holder thereof to purchase a Common Share at $0.10 per share for a period of 36 months from closing, subject to acceleration in the event that the Common Shares trade at or above $0.20 for 30 consecutive trading days.Petrolympic’s Chief Executive Officer, Mendel Ekstein, commented: “In determining who would participate...

SHANGHAI, China, Dec. 02, 2020 (GLOBE NEWSWIRE) — Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, today announced that the China Center for Drug Evaluation, National Medical Products Administration (CDE, NMPA) has recommended Breakthrough Therapy Designation (BTD) for Nefecon for the treatment of IgA nephropathy (IgAN).Nefecon is a potential first-in-disease, oral, targeted-release formulation of budesonide and is currently being investigated in a Phase 3 global registrational study, NefIgArd, to evaluate its efficacy and safety in patients with primary IgAN. Everest is currently enrolling patients as part of the NefIgArd clinical trial to...